Intestinal motor stimulation by the 5-HT4 receptor agonist ML10302: differential involvement of tachykininergic pathways in the canine small bowel and colon.
5-Hydroxytryptamine (5-HT)4 receptor agonists stimulate gut motility through cholinergic pathways, although there are data suggesting that noncholinergic (tachykininergic) excitatory pathways may also be involved. Differences may exist between the small bowel and colon. Our aims were: (i) to compare the prokinetic effect exerted by the 5-HT4 receptor agonist ML10302 in the canine small bowel and colon in vivo; and (ii) to investigate the role of tachykininergic pathways in mediating this response. In fasting, conscious dogs, chronically fitted with electrodes and strain-gauge force transducers along the small bowel and colon, intravenous injection of ML10302 (35 microg kg-1) immediately stimulated spike activity and significantly increased propagated myoelectrical events at both intestinal levels. In the small bowel, the effects of ML10302 were unchanged by previous administration of the selective NK1 tachykinin receptor antagonist SR140333, the NK2 tachykinin receptor antagonist SR48968, or the NK3 tachykinin receptor antagonist SR142801. In the colon, all tachykinin receptor antagonists significantly inhibited stimulation of spike and mechanical activity by ML10302, without affecting ML10302-induced propagated myoelectrical events. Atropine (100 microg kg-1 i.v.) suppressed the stimulatory effect of ML10302 at both intestinal levels. In conclusion, the 5-HT4 receptor agonist ML10302 induced significant prokinesia both in the small bowel and colon through activation of cholinergic pathways. Tachykininergic pathways are not involved in the ML10302-induced prokinesia in the small bowel, but they play an important role in mediating the colonic motor response to ML10302.
De Ponti
F
F
Department of Pharmacology, University of Bologna, Bologna, Italy. deponti@biocfarm.unibo.it
Crema
F
F
Moro
E
E
Nardelli
G
G
Croci
T
T
Frigo
G M
GM
D000465:Algorithms; D062365:Aminobenzoates / Q000494:pharmacology*; D000818:Animals; D003106:Colon / Q000187:drug effects / Q000502:physiology*; D004285:Dogs; D004576:Electromyography; D004594:Electrophysiology; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007421:Intestine, Small / Q000187:drug effects / Q000502:physiology*; D007441:Intubation, Gastrointestinal; D009043:Motor Activity / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology*; D011985:Receptors, Serotonin / Q000187:drug effects*; D044422:Receptors, Serotonin, 5-HT4; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D013268:Stimulation, Chemical; D015320:Tachykinins / Q000502:physiology*; D062366:para-Aminobenzoates
C117947:2-piperidinoethyl 4-amino-5-chloro-2-methoxybenzoate; D062365:Aminobenzoates; D010880:Piperidines; D011985:Receptors, Serotonin; D018039:Receptors, Tachykinin; D017366:Serotonin Receptor Agonists; D015320:Tachykinins; D062366:para-Aminobenzoates; D044422:Receptors, Serotonin, 5-HT4